Alithya Group (NASDAQ:ALYA) reported quarterly losses of $(0.02) per share. This is a 75 percent increase over losses of $(0.08) per share from the same period last year. The company reported $102.90 million in sales
Relationship Will Leverage Be The Match BioTherapies' Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara's Allogeneic T-cell Platform
Be The Match BioTherapies and Atara
Sonos Inc (NASDAQ: SONO) shares are trading lower Thursday after the company reported weak top-line results, issued guidance below analyst estimates and announced a CFO transition.